Asthma affects over 34 million Americans and over 300 million people worldwide. A quarter million people die each year from asthma around the world and asthma prevalence is on the rise. Asthma has increased by 75% since 1980, with incidence increasing by 160% in children.
Now, more than ever, research focused on understanding the mechanisms of asthma are needed to help guide the development of tailored treatments.
The Fahy Lab is located in the Cardiovascular Research Institute and the Department of Medicine at the University of California, San Francisco. Our research program aims to uncover disease mechanisms, develop disease biomarkers, and evaluate novel treatments for asthma and other airway diseases. Our program is truly translational, encompassing clinical trials and investigations in patients and studies of disease mechanisms in cell culture and animal model systems.
The NHLBI Severe Asthma Research Program site at UCSF, directed by Dr. John Fahy, was recently featured on the front page of the SF Chronicle's Health section. Read the article here.
Michael Peters, M.D., Fahy Group Fellow, is the lead author of the Featured Article of the Week on the Journal of Allergy and Clinical Immunology website. This article examines sputum cells as a method to identify substypes of asthma. Congratulations, Dr. Peters!
To participate in the Severe Asthma Research Program, visit the UCSF Airway Clinical Research Center site.
The Fahy Lab is affiliated with:
Airway Clinical Research Center ∙ UCSF Moffitt Hospital, 13th Floor ∙ San Francisco, Ca 94143
Phone: (866) 246-4253 ∙ Fax: (415) 502-7814